ArticleCalcified tissue international2026
Cxcr2 is Required for Osteoclast Regulation, Bone Structure, and Hematological Response During Bone (Re)modeling.
Article in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cxcr2 is a chemokine receptor involved in immune cell trafficking, inflammation, and wound healing that has been implicated in multiple diseases and cancers. However, there is a relative lack of knowledge of the in vivo functions of Cxcr2 in bone cell biology. Here we characterized the skeletal and hematological phenotypes of Cxcr2-deficient mice (Cxcr2 KO) backcrossed onto the FVB/N background. Structural and biomechanical testing demonstrated that Cxcr2 KO caused a significant loss of trabecular and cortical bone volume, altered bone geometry, and an associated loss of bone strength relative to controls. Histological analysis suggests that this is a consequence of increased osteoclast activity in Cxcr2 KO mice, while osteoblasts were not affected. Serum analysis revealed elevated levels of the bone resorption marker CTX-1, with no change in the bone formation marker P1NP, suggesting a shift towards increased osteoclast-mediated bone turnover. While both RANKL and OPG were decreased in Cxcr2 KO bones, the RANKL/OPG ratio was not different compared to WT mice. Additionally, Cxcr2 KO mice displayed systemic immune dysregulation, including elevated serum cytokines and altered hematological parameters, fewer megakaryocytes in bone marrow, higher neutrophil counts in blood, and anisocytosis. Our data point to Cxcr2 as a critical and multifunctional regulator of healthy bone homeostasis, linking immune function with skeletal integrity. This work highlights the Cxcr2 KO model as a valuable system for studying inflammatory bone loss and osteoimmunological interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.